γ-Aminobutyric Acid (GABA): A Complete Guide to Ingredient Quantity Labeling Standards and Cross-Border Regulatory Compliance

---

Abstract

γ-Aminobutyric acid (GABA, CAS No. 56-12-2) is a non-protein amino acid that occurs naturally in plants, microorganisms, and mammalian brain tissue, and has been detected in fermented foods such as kimchi, natto, and aged cheese. With the rollout of Japan's Food with Function Claims (FFC) system, GABA ingredients have attracted growing attention in the health food sector, and products featuring GABA as a primary ingredient are entering cross-border markets in China, Southeast Asia, and North America at an increasing rate.

GABA is not a drug. The information that may lawfully appear on product labels is fundamentally different from what appears on pharmaceutical labeling, and the regulatory status of this ingredient, permissible daily intake limits, and allowable label statements differ materially across jurisdictions. This paper provides a systematic examination of three dimensions: ingredient quantity labeling standards, label compliance frameworks, and cross-border purchase verification methods, offering actionable reference guidance for manufacturers, importers, and end consumers. All regulatory references are based on official documents publicly available as of the date of writing; readers are responsible for verifying their continued currency.

---

I. Ingredient Quantity Labeling Standards for GABA

1.1 Japan: Quantification Requirements Under the Food Labeling Standards

Japan's current labeling regulatory framework is anchored by the *Food Labeling Standards* (Consumer Affairs Agency Notification, effective 2015), operating alongside the *Health Promotion Act* and the *Act against Unjustifiable Premiums and Misleading Representations* to govern health food labeling.

Mandatory Disclosure of Daily Intake

Foods sold for the purpose of "maintaining and promoting health" must state the recommended daily intake and the corresponding GABA content (in mg) in a prominent location on the label. The Food with Function Claims (FFC) system (in effect since 2015) further requires that, if a company intends to include function-related statements on the label concerning GABA, it must file a notification with the Consumer Affairs Agency. The notification package must include:

• A quantitative analysis report for GABA in the ingredient material (using high-performance liquid chromatography, HPLC, or a method of equivalent sensitivity);
• Batch-to-batch content consistency data (coefficient of variation, CV, is typically required to be ≤15%);
• The label declared value must be set as a lower-bound guarantee of the measured value — that is, the labeled amount must not exceed the lowest measured quantity across batches.

GABA Notification Examples Under the Food with Function Claims System

The Consumer Affairs Agency's public database (FLD) has accumulated hundreds of GABA-related notifications, and each notification number and label statement can be individually verified through the official search portal (fld.caa.go.jp). The "Quantity of Functional Ingredient" stated in the notification summary constitutes a quantitative assurance that consumers can rely upon. Once a notification is accepted and publicly posted, the company is not permitted to label actual products with a GABA content lower than the notified amount.

General Health Foods (Non-Notified)

GABA products that have not been notified under the FFC system must follow the nutritional information labeling requirements set out in the schedules of the *Food Labeling Standards*. GABA is listed as "Other Components" at the end of the nutrition facts panel, with the unit expressed as mg/day or mg/tablet (capsule). Any exaggerated or inaccurate content claims are subject to administrative penalties under Article 5, Item 1 of the *Act against Unjustifiable Premiums and Misleading Representations* (misleading quality representations).

1.2 China: Quantitative Management Under the Novel Food Ingredient Framework

The National Health Commission (formerly the Ministry of Health) approved GABA as a novel food ingredient (formerly termed a new resource food ingredient) via Announcement No. 12 of 2009, establishing the following key parameters:

Labeling Requirements

Products using GABA as an ingredient must include on the label:

• 1. The ingredient name: γ- (γ-aminobutyric acid) — the English abbreviation "GABA" alone, without the name, is not permissible;
• 2. The GABA content per serving or per day (in mg), which must not exceed the 500 mg daily limit;
• 3. A warning statement identifying unsuitable populations;
• 4. If the product is positioned as a health food , the manufacturer must hold a "Blue Hat" registration number issued by the National Medical Products Administration (NMPA). The label must fully display the approval number, suitable populations, unsuitable populations, and other legally mandated content, and any function claims may not exceed the approved scope.

-Language Labels on Imported Products

Under Article 97 of the *Food Safety Law*, imported prepackaged foods must bear a -language label that complies with standards. The information on the original-language label must not contradict the label. GABA content stated in must correspond exactly to the original-language label, and units must be expressed in China's statutory units of measurement.

1.3 United States: Structure/Function Claim Boundaries Under the DSHEA Framework

In the United States, GABA supplements are regulated under the *Dietary Supplement Health and Education Act of 1994* (DSHEA). No pre-market approval is required, but the following labeling obligations apply:

• Supplement Facts label: Must list the amount per serving (in mg) and the percent Daily Value (where applicable);
• Structure/function claims must be filed with the FDA within 30 days of marketing, and the label must carry the mandatory disclaimer: *"This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."*
• GMP compliance: 21 CFR Part 111 requires manufacturers to test ingredient content; labeled quantitative values must be supported by testing data;
• GABA is not currently on the FDA's Generally Recognized As Safe (GRAS) list. Companies marketing it as a new dietary ingredient (NDI) must submit a safety notification pursuant to 21 CFR 190.6.

1.4 European Union: Dual Threshold of Novel Food and Health Claims

EU regulation of GABA is subject to two overlapping frameworks:

• 1. Novel Food Regulation (Regulation (EU) 2015/2283): If GABA is determined to have had no significant history of consumption within the EU prior to 15 May 1997, it must obtain novel food authorization before it may be marketed;
• 2. Health Claims Regulation (Regulation (EC) No 1924/2006): The European Food Safety Authority (EFSA) has not issued a favorable scientific opinion on health claims relating to GABA. As matters currently stand, GABA supplements on the markets of EU member states may not in principle bear approved health claims.

---

II. Label Compliance Framework and Prohibited Statements

2.1 Permissible Disclosure Dimensions

Across all jurisdictions discussed, the following types of information constitute compliant quantitative and traceability disclosures:

• Content labeling: The guaranteed minimum measured GABA content per capsule, per sachet, or per daily serving (in mg);
• Ingredient origin and production method: Factual descriptive statements such as "produced by lactic acid bacterial fermentation using glutamic acid as substrate" or "derived from germinated brown rice";
• Third-party testing documentation: Report reference numbers issued by recognized bodies such as JHNFA (Japan Health and Nutrition Food Association), NSF International, or Eurofins;
• GMP certification information: The name of the certifying body and certification number for the manufacturing facility's GMP qualification — a verifiable statement of quality system facts.

As an example, products manufactured at a facility holding JHNFA GMP Compliance Certification (Certification No. 34225) under Tsurumatsui Iyaku / Showa may have that certification number cross-verified in the JHNFA official database. This constitutes publicly verifiable compliance information disclosure, not an efficacy claim.

2.2 Categories of Expressly Prohibited Statements

2.3 How to Verify a Food with Function Claims Notification

Consumers can independently verify whether a product has been duly notified by following these steps:

• 1. Access the Consumer Affairs Agency's Food with Function Claims Notification Information Search page;
• 2. Search by product brand name, company name, or notification number;
• 3. Confirm that the "Name of Functional Ingredient" listed in the notification summary is GABA, and that the daily intake stated there matches what appears on the physical product label;
• 4. Confirm that the notification status shows "Notified" — not withdrawn or returned for revision.

---

III. Compliance Considerations for Cross-Border Purchases

3.1 Consumers Purchasing GABA Products from Japan

Personal Use Import Allowances

Under General Administration of Customs Announcement No. 26 (2016) and related cross-border e-commerce policies, personal-use imports must fall within reasonable quantity limits. GABA supplements are classified as ordinary health food, not drugs. Under normal circumstances they may be declared as personal-use goods upon entry, but stockpiling in large quantities may be reclassified as commercial importation, requiring customs clearance through commercial import procedures.

-Language Label Compliance

Imported food entering China through cross-border e-commerce channels (Comprehensive Pilot Zone model) is eligible, under current policy and only within applicable pilot zone scope, for a labeling accommodation arrangement — though an electronic -language description must accompany the product. Food imported through general trade channels must bear a -language label that complies with GB 7718. Where a consumer receives a product in its original packaging with no -language information whatsoever, a degree of compliance risk exists.

Ingredient Content Verification

Upon receipt of a product, consumers should verify that: the declared GABA content does not exceed 500 mg/day; the packaging displays a warning identifying unsuitable populations (infants, young children, pregnant women); and where no such -language information is present, preference should be given to products that have a notification on record with the Consumer Affairs Agency and provide transparent ingredient quantity information.

3.2 U.S. Consumers Purchasing from Japan

FDA Import Requirements

The U.S. FDA takes a generally permissive stance on personal imports of dietary supplements (Personal Importation Policy), but products must meet the basic requirements of DSHEA and may not be promoted for pharmaceutical purposes. An English-language label or English-language documentation must be available.

New Dietary Ingredient (NDI) Considerations

If GABA is considered a new dietary ingredient in the U.S. market, consumers purchasing products for which no NDI notification has been filed are acquiring products with a compliance deficiency at the regulatory level — though enforcement in such cases is typically directed at manufacturers and importers rather than individual consumers.

3.3 Assessing the Credibility of Third-Party Test Reports

When evaluating the reliability of ingredient quantity claims for cross-border products, consumers should look for the following verifiable elements:

• Testing laboratory accreditation: The issuing laboratory should hold ISO/IEC 17025 accreditation;
• Analytical method: Quantitative analysis of GABA typically employs HPLC-UV or HPLC with fluorescence detection (FLD); the report should specify the method used and the limit of detection;
• Batch traceability: The batch number shown on the test report must be traceable to the batch number of the physical product;
• Client of record: The party commissioning the report should be the product manufacturer or an authorized distributor, not an unrelated third party.

---

IV. Actionable Guidance for Consumers

• 1. Prioritize products with filed notifications: When purchasing GABA products in Japan, use the Consumer Affairs Agency's FLD database to confirm whether the product holds a valid Food with Function Claims notification. The ingredient content stated in the notification represents a quantity guarantee on the official public record.
• 2. Verify content against the regulatory ceiling: For products destined for mainland China, confirm that the GABA content per daily serving does not exceed 500 mg. Products exceeding this limit do not have legal standing for commercial distribution in the market.
• 3. Authenticate GMP certification information: The GMP Compliance Certification status and validity period for a manufacturing facility can be verified on the JHNFA website. Confirm the authenticity of the certification number to avoid products bearing fabricated certification claims.
• 4. Avoid products making therapeutic claims: In all major markets, any product label using terms such as "treats," "prevents," "diagnoses," or "cures" is non-compliant. The presence of such language is itself a signal that the product does not meet compliance standards.
• 5. Retain purchase documentation: When purchasing cross-border products, it is advisable to keep order records from the purchasing platform, photographs of the batch number on the packaging, and any test reports provided by the seller, to support any subsequent traceability needs.
• 6. Do not substitute price for compliance judgment: A high price does not guarantee compliance; a low price does not necessarily signal low quality. The transparency of ingredient quantity labeling, notification or certification status, and the availability and verifiability of test reports are objective criteria for assessing the credibility of product information, and are independent of price.

---

Conclusion

The compliance foundation for GABA products rests on ingredient content that is quantifiable, traceable, and independently verifiable — not on any claim or promise of health outcomes. Japan's public notification mechanism under the Food with Function Claims system, China's daily use limit for novel food ingredients, the U.S. Supplement Facts mandatory labeling requirements under DSHEA, and the EU's novel food authorization framework together constitute the institutional safeguards that different markets have established to ensure information transparency for GABA products.

For cross-border consumers, understanding the key quantitative standards and compliance verification pathways in each jurisdiction is a fundamental tool for making informed decisions in an environment of information asymmetry. For manufacturers, at the stages of label design and market entry, "labeling compliance before efficacy promotion" must be treated as a non-negotiable baseline — and long-term brand credibility is built on the transparency of quantitative data.

---

*This document is provided for informational purposes only and does not constitute legal, medical, or investment advice. Regulatory provisions are subject to change; readers should verify the current version of all cited requirements before making any commercial or consumer decisions.*